The THEMIS trial of Brilinta/Brilique (ticagrelor) in combination with aspirin in patients with coronary artery disease (CAD) and type 2 diabetes with no prior heart attack or stroke will give a modest boost to sales but is unlikely to prevent the product being overtaken by Farxiga in AstraZeneca PLC’s CV portfolio.
THEMIS was one of two positive Phase III studies unveiled on Sunday at the European Society of Cardiology (ESC) annual congress in Paris, France, but was overshadowed by the DAPA-HF trial of Farxiga (dapagliflozin)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?